Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry.

Détails

ID Serval
serval:BIB_D36A955A51B2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry.
Périodique
Eurointervention
Auteur(s)
Wenaweser P., Stortecky S., Heg D., Tueller D., Nietlispach F., Falk V., Pedrazzini G., Jeger R., Reuthebuch O., Carrel T., Räber L., Amann F.W., Ferrari E., Toggweiler S., Noble S., Roffi M., Gruenenfelder J., Jüni P., Windecker S., Huber C.
ISSN
1969-6213 (Electronic)
ISSN-L
1774-024X
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
10
Numéro
8
Pages
982-989
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
AIMS: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) using CE-mark approved devices in Switzerland.
METHODS AND RESULTS: The Swiss TAVI registry is a national, prospective, multicentre, monitored cohort study evaluating clinical outcomes in consecutive patients undergoing TAVI at cardiovascular centres in Switzerland. From February 2011 to March 2013, a total of 697 patients underwent TAVI for native aortic valve stenosis (98.1%), degenerative aortic bioprosthesis (1.6%) or severe aortic regurgitation (0.3%). Patients were elderly (82.4±6 years), 52% were females, and the majority highly symptomatic (73.1% NYHA III/IV). Patients with severe aortic stenosis (mean gradient 44.8±17 mmHg, aortic valve area 0.7±0.3 cm²) were either deemed inoperable or at high risk for conventional surgery (STS 8.2%±7). The transfemoral access was the most frequently used (79.1%), followed by transapical (18.1%), direct aortic (1.7%) and subclavian access (1.1%). At 30 days, rates of all-cause mortality, cerebrovascular events and myocardial infarction were 4.8%, 3.3% and 0.4%, respectively. The most frequently observed adverse events were access-related complications (11.8%), permanent pacemaker implantation (20.5%) and bleeding complications (16.6%). The Swiss TAVI registry is registered at ClinicalTrials.gov (NCT01368250).
CONCLUSIONS: The Swiss TAVI registry is a national cohort study evaluating consecutive TAVI procedures in Switzerland. This first outcome report provides favourable short-term clinical outcomes in unselected TAVI patients.
Pubmed
Web of science
Création de la notice
06/03/2015 19:16
Dernière modification de la notice
20/08/2019 15:53
Données d'usage